Prognosis After Pacemaker Implantation in Alcohol Septal Ablation

One of the main complications of alcohol septal ablation (ASA) is the alteration in the conduction system, which could lead to permanent pacemaker (PPM) implantation. This is mainly due to the relationship between septal perfusion and the conduction system (especially the right bundle branch). The incidence reported in the literature is 7% to 20% of all cases.

Pronóstico post implante de marcapasos en ablación septal con alcohol

The aim of this research was to determine the short- and long-term endpoints of patients who required PPM implantation for high-grade atrioventricular block after ASA. Data from the multinational Euro-ASA Registry were analyzed.

Patients with PPM were studied and propensity score matching was conducted to group them and compare them with subjects without device implantation.

The endpoints analyzed were 30-day all-cause mortality, all-cause mortality at the long-term follow-up, long-term functional class, long-term outflow tract gradient, and reintervention rate. The mean follow-up was 4.9 years.

The PPM implantation rate was 9.4% at 30 days and there was an additional 3.1% at follow-up. The pooled cohort comprised 278 patients; 139 in the PPM arm and 139 in the non-PPM arm. Mortality at 30 days was 0.4%, with no significant differences between groups. Patients with PPM generally presented previous bundle branch block (= 0.01), were treated with a higher dose of alcohol (p = 0.03), and had a more marked gradient reduction (p ≤ 0.01).

Read also: Is Right Ventricle-Pulmonary Artery (RV-PA) Coupling Important in Low Risk TAVR?

The multivariate analysis identified age and the presence of previous bundle branch block as predictors of all-cause mortality.

The baseline predictors of PPM implantation were higher age range, worse functional class, higher alcohol dose, and the presence of previous block.

Conclusion

In the Euro-ASA Registry, PPM implantation did not lead to higher mortality. Considering that these are data obtained from a large registry, the sample of 278 patients was limited, which is an important hypothesis generator.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring

Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...

AHA 2025 | CLOSURE-AF: Left Atrial Appendage Occlusion (LAAO) vs. Medical Therapy in Atrial Fibrillation with High Stroke and Bleeding Risk

Atrial fibrillation (AF) is a complex condition in which patients often present with multiple comorbidities, including high bleeding risk. Percutaneous left atrial appendage occlusion...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

TCT 2025 | ANDES Trial: Short-Term DOAC vs. DAPT After Percutaneous Left Atrial Appendage Occlusion

Percutaneous left atrial appendage occlusion (LAAO) is an established alternative to chronic anticoagulation in patients with non-valvular atrial fibrillation (AFib). A clinically relevant complication...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring

Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...